No information is available on the clinical use of gefitinib during breastfeeding. Because gefitinib is 90% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 48 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during gefitinib therapy.
关于吉非替尼在母乳喂养期间的临床应用尚无可用信息。由于吉非替尼与血浆蛋白的结合率为90%，乳汁中的含量可能较低。然而，其半衰期约为48小时，可能会在婴儿体内蓄积。制造商建议在吉非替尼治疗期间停止母乳喂养。
